… erlotinib, an EGFR tyrosine kinase inhibitor (TKI), in patients with c-Met–positive (+) NSCLC.
PATIENTS … every 21 days) plus erlotinib (150 mg once daily) in adult patients (age ≥ 18 …

… erlotinib would be safe and show efficacy in patients with EGFR-mutated tumors experiencing
disease progression on erlotinib … patients with EGFR WT tumors with MET dysregulation. …

… most commonly mutated oncogene in non-small cell lung cancer (NSCLC), occurring mainly
in lung adenocarcinomas (30%) and less frequently in squamous cell carcinoma (5%) (2, 3) …

… Erlotinib is currently approved as first-line treatment of locally advanced or metastatic non–small
cell lung cancer … with erlotinib, 2 the recent marketing authorization of generic options for …

… Erlotinib is an epidermal growth factor receptor (EGFR) … -cell lung cancer (NSCLC). Skin
rash and diarrhea are well-known and common adverse events in patients receiving erlotinib, …

… with erlotinib could enhance antitumor immunity and extend efficacy in these patients. …
Liver toxicity was not observed in the patients treated with pembrolizumab plus erlotinib, …

… cancer-related deaths, deaths from lung cancer are the most common worldwide, and
approximately 85% of lung cancers are classified as non-small cell lung cancer … cancer cell growth …

… First-line gefitinib for patients with advanced non–small-cell lung cancer harboring … First-line
gefitinib for patients with advanced non–small-cell lung cancer harboring epidermal growth …

… anti-tumor efficacy. The Phase III RELAY trial demonstrated superior PFS for ramucirumab
plus erlotinib (RAM + ERL) over placebo plus erlotinib (… in Western versus Asian patients. This …

… Patients with stage IIIB/IV or postoperative recurrent NSCLC were randomized to receive oral
erlotinib 150 mg once daily (n = 77) or erlotinib … in patients with non-small cell lung cancer: …